SREBF1 and fatty liver disease: Similar to HDCA, cholane and cholestane Lxr agonists might be useful for this purpose: while such ligands induce transcription of the master transcription factor driving de novo lipogenesis Srebf1, they simultaneously block Srebf1 proteolytic maturation by stabilizing the precursor in the endoplasmic reticulum, thereby avoiding the induction of hypertriglyceridemia and hepatic steatosis (Kaneko et al., 2003; Quinet et al., 2004; Peng et al., 2008, 2011; Kratzer et al., 2009).